Novartis AG's latest marketcap:
As of 07/05/2025, Novartis AG's market capitalization has reached $242.35 B. According to our data, Novartis AG is the 51th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 242.35 B |
| Revenue (ttm) | 53.22 B |
| Net Income (ttm) | 12.86 B |
| Shares Out | 1.96 B |
| EPS (ttm) | 6.38 |
| Forward PE | 14.62 |
| Ex-Dividend Date | 03/12/2025 |
| Earnings Date | 07/17/2025 |
Novartis AG's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $242.35 B | 23.97% | 51 |
| 12/31/2024 | $194.55 B | -6.26% | 67 |
| 12/29/2023 | $207.54 B | 5.57% | 53 |
| 12/30/2022 | $196.59 B | 0.47% | 44 |
| 12/31/2021 | $195.68 B | -9.46% | 60 |
| 12/31/2020 | $216.12 B | -1.25% | 39 |
| 12/31/2019 | $218.84 B | 10.05% | 35 |
| 12/31/2018 | $198.86 B | -0.23% | 30 |
| 12/29/2017 | $199.33 B | 15.27% | 33 |
| 12/30/2016 | $172.91 B | -16.21% | 32 |
Company Profile
About Novartis AG
Novartis AG is a global pharmaceutical company headquartered in Basel, Switzerland. Founded in 1996, the company specializes in the research, development, manufacturing, and distribution of innovative medicines across multiple therapeutic areas.
Key Products
- Entresto – Treats chronic heart failure with reduced ejection fraction (HFrEF).
- Cosentyx – Used for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- Kisqali – A selective CDK4/6 inhibitor for cancer treatment.
- Promacta/Revolade – Addresses immune thrombocytopenia (ITP) and severe aplastic anemia (SAA).
- Tafinlar + Mekinist – Oral combination therapy for specific cancers.
- Jakavi – Treats myelofibrosis, polycythemia vera, and graft-versus-host disease (GvHD).
- Zolgensma – A gene therapy for spinal muscular atrophy.
- Leqvio – Reduces LDL cholesterol in collaboration with Alnylam Pharmaceuticals.
Therapeutic Focus Areas
- Cardiovascular, Renal & Metabolic Diseases
- Immunology
- Neuroscience
- Oncology & Hematology
Partnerships & Collaborations
Novartis has a strategic collaboration with Alnylam Pharmaceuticals for the development and commercialization of Leqvio (inclisiran), an LDL cholesterol-lowering therapy.
The company continues to innovate in pharmaceuticals, delivering life-changing treatments to patients worldwide.
Frequently Asked Questions
-
What is Novartis AG's (NVS) current market cap?As of 07/05/2025, Novartis AG (including the parent company, if applicable) has an estimated market capitalization of $242.35 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Novartis AG (NVS) rank globally by market cap?Novartis AG global market capitalization ranking is approximately 51 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.